{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:14Z","timestamp":1753892114671,"version":"3.41.2"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the effect of DCCBs on CKD progression in DM patients with CKD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> One million individuals were randomly sampled from Taiwan\u2019s National Health Insurance Research Database. The study cohort consisted of DM patients with CKD who used DCCBs. The comparison cohort was propensity-matched for demographic characteristics and comorbidities. The endpoint was advanced CKD or end-stage renal disease (ESRD). The Cox proportional hazards model was used to calculate the risks.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 9,761 DCCB users were compared with DCCB nonusers at a ratio of 1:1. DCCB users had lower risk of advanced CKD and ESRD than nonusers\u2014with adjusted hazard ratio [aHR; 95% confidence interval (CI)] of 0.64 (0.53\u20130.78) and 0.59 (95% CI, 0.50\u20130.71) for advanced CKD and ESRD, respectively. DCCB users aged \u226565\u00a0years had the lowest incidence rates of advanced CKD and ESRD\u2014with aHR (95% CI) of 0.47 (0.34\u20130.65) and 0.48 (0.35\u20130.65) for advanced CKD and ESRD, respectively. Finally, cumulative DCCB use for &amp;gt;1,100\u00a0days was associated with the lowest advanced CKD and ESRD risks [(aHR, 0.29 (95% CI, 0.19\u20130.44)].<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> DM patients with CKD who used DCCBs had lower risk of progression to advanced CKD and ESRD than nonusers did.<\/jats:p>","DOI":"10.3389\/fphar.2022.786203","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T14:10:07Z","timestamp":1646835007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Shih-Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Huei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Y.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease","volume":"363","author":"Appel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019","volume":"42","author":"Association","year":"2019","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium Channel Blockers versus Other Antihypertensive Therapies on Progression of NIDDM Associated Nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal Outcomes with Different Fixed-Dose Combination Therapies in Patients with Hypertension at High Risk for Cardiovascular Events (ACCOMPLISH): a Prespecified Secondary Analysis of a Randomised Controlled Trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM198212233072605","article-title":"Mechanism of Action of Calcium-Channel-Blocking Agents","volume":"307","author":"Braunwald","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1573403x10666140214122234","article-title":"Coronary Artery Disease in Patients with Chronic Kidney Disease: a Clinical Update","volume":"9","author":"Cai","year":"2013","journal-title":"Curr. Cardiol. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1097\/00004872-199715120-00093","article-title":"The Natriuretic Effect of Nifedipine Gastrointestinal Therapeutic System Remains Despite the Presence of Mild-To-Moderate Renal Failure","volume":"15","author":"Campo","year":"1997","journal-title":"J. Hypertens."},{"key":"B8","doi-asserted-by":"publisher","first-page":"F1015","DOI":"10.1152\/ajprenal.1989.256.6.F1015","article-title":"Disparate Effects of Ca Channel Blockade on Afferent and Efferent Arteriolar Responses to ANG II","volume":"256","author":"Carmines","year":"1989","journal-title":"Am. J. Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.HYP.0000167121.14254.a0","article-title":"Kidney in Early Atherosclerosis","volume":"45","author":"Chade","year":"2005","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/bmj.305.6860.981","article-title":"Comparison of Enalapril and Nifedipine in Treating Non-insulin Dependent Diabetes Associated with Hypertension: One Year Analysis","volume":"305","author":"Chan","year":"1992","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2215\/cjn.07440618","article-title":"Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines","volume":"14","author":"Chang","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/HJH.0b013e3283281254","article-title":"Calcium Channel Blockers and Cardiovascular Outcomes: a Meta-Analysis of 175,634 Patients","volume":"27","author":"Costanzo","year":"2009","journal-title":"J. Hypertens."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1001\/archinte.164.22.2459","article-title":"Clinical Significance of Renal Function in Hypertensive Patients at High Risk: Results from the INSIGHT Trial","volume":"164","author":"de Leeuw","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MAJ.0b013e3181d658c4","article-title":"Combination Therapy of Calcium Channel Blocker and Angiotensin II Receptor Blocker Reduces Augmentation index in Hypertensive Patients","volume":"339","author":"Doi","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium Channel Blockers: an Update","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-insulin-dependent Diabetes and Hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.jhh.1001279","article-title":"Effect of Two Antihypertensive Combinations on Metabolic Control in Type-2 Diabetic Hypertensive Patients with Albuminuria: a Randomised, Double-Blind Study","volume":"15","author":"Fern\u00e1ndez","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"B18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10641963.2020.1783547","article-title":"Association between Diabetes Mellitus and central Arterial Stiffness in Elderly Patients with Systemic Arterial Hypertension","volume":"42","author":"Galv\u00e3o","year":"2020","journal-title":"Clin. Exp. Hypertens."},{"volume-title":"New Therapeutics For Traumatic Brain Injury","year":"2017","author":"Gurkoff","key":"B19"},{"key":"B20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1742-1241.2008.01713.x","article-title":"Effective Management of Hypertension with Dihydropyridine Calcium Channel Blocker-Based Combination Therapy in Patients at High Cardiovascular Risk","volume":"62","author":"Haller","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00004872-200502000-00028","article-title":"Controlled-release Nifedipine and Candesartan Low-Dose Combination Therapy in Patients with Essential Hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study","volume":"23","author":"Hasebe","year":"2005","journal-title":"J. Hypertens."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1093\/eurheartj\/ehq139","article-title":"Effects of a Fixed Combination of Perindopril and Indapamide in Patients with Type 2 Diabetes and Chronic Kidney Disease","volume":"31","author":"Heerspink","year":"2010","journal-title":"Eur. Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neulet.2018.02.027","article-title":"Calcium Channel Blocker Use Reduces Incident Dementia Risk in Elderly Hypertensive Patients: A Meta-Analysis of Prospective Studies","volume":"671","author":"Hussain","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/10641963.2010.503299","article-title":"Combination of Angiotensin II Receptor Antagonist with Calcium Channel Blocker or Diuretic as Antihypertensive Therapy for Patients with Chronic Kidney Disease","volume":"33","author":"Ishimitsu","year":"2011","journal-title":"Clin. Exp. Hypertens."},{"key":"B25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1291\/hypres.28.513","article-title":"The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): Protocol, Patient Characteristics, and Blood Pressure during the First 12 Months","volume":"28","author":"JATOS","year":"2005","journal-title":"Hypertens. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1523-1755.2005.00406.x","article-title":"Atherosclerotic Renovascular Disease in United States Patients Aged 67 Years or Older: Risk Factors, Revascularization, and Prognosis","volume":"68","author":"Kalra","year":"2005","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000205521","article-title":"Add-on Benefits of Amlodipine and Thiazide in Nondiabetic Chronic Kidney Disease Stage 1\/2 Patients Treated with Valsartan","volume":"32","author":"Kaneshiro","year":"2009","journal-title":"Kidney Blood Press. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.160.12.1849","article-title":"Use of Calcium Channel Blockers and Risk of Hospitalized Gastrointestinal Tract Bleeding","volume":"160","author":"Kaplan","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"B29","first-page":"71","article-title":"Effects of a Calcium Antagonist and an Angiotensin II Receptor Antagonist on Rat Renal Arterioles","volume":"5","author":"Kimura","year":"1994","journal-title":"Blood Press. Suppl."},{"key":"B30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12325-009-0015-8","article-title":"Fixed-dose Manidipine\/delapril versus Losartan\/hydrochlorothiazide in Hypertensive Patients with Type 2 Diabetes and Microalbuminuria","volume":"26","author":"Kohlmann","year":"2009","journal-title":"Adv. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1253\/circj.cj-11-0141","article-title":"Azelnidipine and Amlodipine Anti-coronary Atherosclerosis Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Juntendo University (ALPS-J)","volume":"75","author":"Kojima","year":"2011","journal-title":"Circ. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1681\/ASN.2016030326","article-title":"BP Control and Long-Term Risk of ESRD and Mortality","volume":"28","author":"Ku","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pds.3781","article-title":"Calcium Channel Blocker Use and Risk of Parkinson's Disease: a Meta-Analysis","volume":"24","author":"Lang","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.clinthera.2012.06.014","article-title":"Comparison of the Efficacy and Safety Profiles of Two Fixed-Dose Combinations of Antihypertensive Agents, Amlodipine\/benazepril versus Valsartan\/hydrochlorothiazide, in Patients with Type 2 Diabetes Mellitus and Hypertension: a 16-week, Multicenter, Randomized, Double-Blind, Noninferiority Study","volume":"34","author":"Lee","year":"2012","journal-title":"Clin. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.109.131466","article-title":"Differential Effects between a Calcium Channel Blocker and a Diuretic when Used in Combination with Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients","volume":"54","author":"Matsui","year":"2009","journal-title":"Hypertension"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and normal Blood Pressure: the CAMELOT Study: a Randomized Controlled Trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1097\/01.asn.0000034687.62568.9b","article-title":"Cardiovascular and Renal protection in Type 2 Diabetes Mellitus: the Role of Calcium Channel Blockers","author":"Nosadini","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1097\/HJH.0000000000000281","article-title":"Combinations of Olmesartan and a Calcium Channel Blocker or a Diuretic in Elderly Hypertensive Patients: a Randomized, Controlled Trial","volume":"32","author":"Ogihara","year":"2014","journal-title":"J. Hypertens."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1097\/00005344-198812006-00017","article-title":"Cardiovascular Drugs and Atherosclerosis: Effects of Calcium Antagonists, Beta-Blockers, and Nitrates on Atherosclerotic Characteristics of Human Aortic Cells","author":"Orekhov","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/10641963.2013.810227","article-title":"Angiotensin Receptor Blocker (ARB)-diuretic versus ARB-Calcium Channel Blocker Combination Therapy for Hypertension Uncontrolled by ARB Monotherapy","volume":"36","author":"Oshikawa","year":"2014","journal-title":"Clin. Exp. Hypertens."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal Dysfunction Complicating the Treatment of Hypertension","volume":"347","author":"Palmer","year":"2002","journal-title":"N. Engl. J. Med."},{"article-title":"Performing a 1: N Case-Control Match on Propensity Score","year":"2012","author":"Parsons","key":"B43"},{"key":"B44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2215\/cjn.07800811","article-title":"Long-term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR","volume":"7","author":"Rahman","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1681\/ASN.2005121319","article-title":"Importance of Blood Pressure Control in Chronic Kidney Disease","volume":"17","author":"Ravera","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(05)71082-5","article-title":"Blood-pressure Control for Renoprotection in Patients with Non-diabetic Chronic Renal Disease (REIN-2): Multicentre, Randomised Controlled Trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2165\/00003495-200464160-00006","article-title":"Drug-gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy","volume":"64","author":"Schelleman","year":"2004","journal-title":"Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.03.117","article-title":"An Operational Definition of SHATS (Systemic Hemodynamic Atherosclerotic Syndrome): Role of Arterial Stiffness and Blood Pressure Variability in Elderly Hypertensive Subjects","volume":"263","author":"Scuteri","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0140-6736(97)05381-6","article-title":"Randomised Double-Blind Comparison of Placebo and Active Treatment for Older Patients with Isolated Systolic Hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/a:1007820401377","article-title":"Predicting Response to Chronic Antihypertensive Treatment with Fosinopril: the Role of Angiotensin-Converting Enzyme Gene Polymorphism","volume":"14","author":"Stavroulakis","year":"2000","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2337\/diab.45.2.216","article-title":"Effects of Cilazapril and Amlodipine on Kidney Function in Hypertensive NIDDM Patients","volume":"45","author":"Velussi","year":"1996","journal-title":"Diabetes"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1161\/01.CIR.82.6.1940","article-title":"A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis","volume":"82","author":"Waters","year":"1990","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1161\/01.cir.84.6.2598","article-title":"Proischemic Complications of Dihydropyridine Calcium Channel Blockers","volume":"84","author":"Waters","year":"1991","journal-title":"Circulation"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.786203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T14:10:25Z","timestamp":1646835025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.786203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":53,"alternative-id":["10.3389\/fphar.2022.786203"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.786203","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"786203"}}